[Experimental study of anti-atherosclerosis potency by lycium seed oil and its possible mechanism].
OBJECTIVE
To study the effect of anti-atherosclerosis of Lycium Seed Oil (Lso) and its possible mechanism.


METHODS
The rabbit atherosclerosis model was established by high fat diet, and the TC, TG, LDL-C, HDL-C levels in plasma were examined dynamically. The SOD, GSH-PX, T-AOC activities and the MDA levels in serum were monitored after 8 week's high fat diet. Aorta samples were observed for atherosclerotic extent, and NF-kappaB, TNF-alpha were assessed by immuno-histochemical method. The lovastatin was set up as a positive control.


RESULTS
contents of HDL-C obviously increased in Plasma of low and high dosage groups and TC, TG, LDL-C levels significantly decreased compared with control group. The SOD, GSH-PX, T-AOC activities up-regulated while the NF-kappaB, MDA and NF-alpha levels decreased in Lycium Seed Oil groups compared with control group. Aortic atherosclerotic extent and area in low dosage and high dosage LSO groups were absolutely smaller than that in high fat diet group. The anti-atherosclerosis potency of Lycium Seed Oil was similar with that of lovastatin.


CONCLUSIONS
Lycium Seed Oil has potent anti-atherosclerosis effects and its anti-atherosclerosis potency was similar with The lovastatin. The possible mechanism involve the decreasing of plasma lipids, anti-peroxidation, inhibiting the activation of NF-kappaB and down-regulating the inflammation cytokines of TNF-alpha.
Jiang
Yi-Deng
YD
Department of Pathophysiology, Sichuan University, Chengdu 610041, China. jwcjyd@163.com
Cao
Jun
J
Dong
Quan-Zhou
QZ
Wang
Shu-Ren
SR
D000818:Animals; D000975:Antioxidants / Q000494:pharmacology / Q000627:therapeutic use; D001011:Aorta / Q000378:metabolism / Q000473:pathology; D001161:Arteriosclerosis / Q000097:blood / Q000473:pathology / Q000517:prevention & control*; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D005260:Female; D005979:Glutathione Peroxidase / Q000097:blood; D000960:Hypolipidemic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D007150:Immunohistochemistry; D015227:Lipid Peroxidation / Q000187:drug effects; D008055:Lipids / Q000097:blood; D032305:Lycium / Q000737:chemistry*; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D016328:NF-kappa B / Q000235:genetics / Q000378:metabolism; D010938:Plant Oils / Q000494:pharmacology* / Q000627:therapeutic use; D011817:Rabbits; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012639:Seeds / Q000737:chemistry; D013482:Superoxide Dismutase / Q000097:blood; D014280:Triglycerides / Q000097:blood; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics / Q000378:metabolism
D000975:Antioxidants; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D000960:Hypolipidemic Agents; D008055:Lipids; D016328:NF-kappa B; D010938:Plant Oils; D014280:Triglycerides; D014409:Tumor Necrosis Factor-alpha; D008315:Malondialdehyde; D002784:Cholesterol; D005979:Glutathione Peroxidase; D013482:Superoxide Dismutase